Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus DOCEFREZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus DOCEFREZ.
CEFACLOR vs DOCEFREZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Docetaxel binds to beta-tubulin, promoting microtubule assembly and inhibiting depolymerization, resulting in cell cycle arrest at G2/M phase and apoptosis.
250-500 mg orally every 8 hours
75 mg/m² intravenously over 1 hour every 3 weeks.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Terminal elimination half-life is 4.5-6.0 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateWarfarin + Cefaclor
"Warfarin may increase the anticoagulant activities of Cefaclor."
Clinical Note
moderatePhenprocoumon + Cefaclor
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Primarily renal excretion (70-80% as unchanged drug) with hepatic metabolism contributing to biliary/fecal elimination (20-30%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefaclor."